P21 Research for Alzheimer's Disease Research
An evidence-based overview of research examining P21 in the context of alzheimer's disease research. This page synthesizes findings from peer-reviewed literature.
Research Summary
Multiple preclinical studies have examined P21 in transgenic Alzheimer's mouse models (3xTg-AD). Research showed reduced tau hyperphosphorylation, decreased amyloid pathology, and improved cognitive function (Kazim et al., 2014, 2016). These findings remain limited to animal models with no human translation data.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Alzheimer's Disease Research
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. P21 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.